Biotech Investment and Business Trends: Weathering the Economic Storm
Decision Resources, Inc, June 2010, Pages: 33
After the disastrous stock market crash of 2008 and ensuing global economic crisis, the biotech industry is showing some signs of recovery. In 2009, overall fundraising was up and corporate partnering activity was robust. Although investors remain jittery, biotech stocks have been increasing since March 2009, giving more companies access to public equity. Nevertheless, factors such as economic volatility, healthcare reform, barriers to early-stage financing of innovation, and an increasingly hostile reimbursement environment are all contributing to uncertainty for the future of the biotech industry.
Questions answered in this report:
- The initial public offering (IPO) window cracked open in 2009 for the biotech industry. What types of therapeutic life sciences companies were able to go public in 2009? How much capital did they raise? What can companies expect from the 2010 public markets?
- Despite the ongoing impact of the recent economic downturn, venture capitalists (VCs) continued investing in biotech companies in 2009. What types of biotech companies are attracting VC investments? Which technologies are attracting the biggest VC investments?
- Although merger and acquisition (M&A) activity in 2009 was lower than many observers expected, biotech companies continued to merge and be acquired. What are the current trends in pharma-biotech and biotech-biotech M&As? What factors drove M&A activity in 2009? How has the structure of biotech M&As evolved in recent years?
- Corporate partnerships were the most reliable source of funding for the biotech industry in 2009. Are early-stage deals attracting significant investment from pharmaceutical companies? How are pharmaceutical companies reducing their level of risk in biotech licensing deals?
- Raising sufficient capital to support early-stage development programs is becoming increasingly difficult. What alternative financing and development strategies are available to biotech companies? What companies are implementing these alternatives?
- The ability to gain reimbursement of drugs is becoming an increasingly important factor for biotech. What impact will healthcare reform in the United States have on the biotech industry? How is the reimbursement environment changing?
Scope of the report:
- Public equity financing: The biotech IPO window; focus of IPO companies.
- Private equity financing: VC investment; focus of companies raising VC capital; high-value investments.
- Mergers and acquisitions: Trends in current high-value, strategic pharma-biotech, and biotech-biotech M&As; factors driving M&As; technologies of M&A companies.
- Corporate partnerships: Impact of the economic downturn; trends in corporate partnerships; option-based agreements; deal structures; area of focus for high-value alliances.
- Outlook for biotech investment and trends: Expectations for public and private equity financing and corporate partnering; alternative financing and development strategies; impact of healthcare reform; reimbursement of targeted therapies.
Key terms for this report:
Biotech industry, Biotechnology, Corporate alliance, Corporate partnership, Deals, Initial public offering (IPO), Licensing, Mergers and acquisitions (M&As), Private equity, Public equity, Strategic alliance, Venture capital, Virtualization
Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
Public and Private Equity Financing
- The IPO Window: Will It Open Wider in 2010?
- Venture Capital Investment
Corporate Partnerships and Alliances
- Trends in Biotech Dealmaking
- GlaxoSmithKline/Concert Pharmaceuticals
- Sanofi -Aventis/Exelixis
- Roche/Plexxikon
Mergers & Acquisitions
Outlook for the Biotech Industry
- Alternative Models for Early-Stage Drug Discovery: Project Financing and Virtualization
- Healthcare Reform
- The Price of Targeted Therapies
Tables
1. Patent Expirations for Select Blockbuster Drugs
2. Biotech Initial Public Offerings, 2009
3. Top Life Sciences Therapeutic Venture Capital Financings, 2009
4. Select High-Value Discovery and Preclinical Corporate Partnerships, 2009
5. Select High-Value Clinical Corporate Partnerships, 2009
6. High-Value Pharma-Pharma and Pharma-Biotech Mergers and Acquisitions, 2009
7. High-Value Biotech-Biotech Mergers and Acquisitions, 2009
Figures
1. R&D Spending vs. FDA New Molecular Entity Approvals: 1997-2009
2. NASDAQ Biotechnology Index, January 2007-April 2010
3. Biotech Quarterly Initial Public Offerings and Venture Capital Investments: Q1 2002-Q1 2010
- Abbott Laboratories
- Acadia Pharmaceuticals
- Acorda Therapeutics
- Adamas Pharmaceuticals
- Aeterna Zentaris
- Aileron Therapeutics
- Alder Biopharmaceuticals
- Algeta
- Alnylam Pharmaceuticals
- Ambit Biosciences
- Amylin Pharmaceuticals
- Anacor Pharmaceuticals
- Apitope
- Arana Therapeutics
- Ardea Biosciences
- Astellas Pharma
- Astex Therapeutics
- AstraZeneca
- Athersys
- Bayer HealthCare
- Bayer Schering Pharma
- Bayhill Therapeutics
- Biogen Idec
- BiolineRX
- BioMarin Pharmaceutical
- Bioniche
- Biotica Technology
- Biovail
- BioVex
- Biovitrum
- BiPar Sciences
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Calixa Therapeutics
- Canbas
- Cardiome Pharma
- Catalyst Biosciences
- Celgene
- Cellerix
- Cempra Pharmaceuticals
- Cephalon
- China Nuokang Bio-Pharmaceuticals
- Chroma Therapeutics
- Clinical Data
- Clovis Oncology
- CombinatoRx
- Concert Pharmaceuticals
- Corthera
- Cougar Biotechnology
- Crucell
- Cubist Pharmaceuticals
- Cumberland Pharmaceuticals
- CV Therapeutics
- D. Western Therapeutics Institute
- Dainippon Sumitomo Pharma
- D-Pharm
- Eli Lilly
- Endo Pharmaceuticals
- Enobia Pharma
- Ensemble Discovery
- Enzon Pharmaceuticals
- Epistem
- Epizyme
- Evolva
- Evotec
- Exelixis
- Exponential Pharma Ventures
- Facet Biotech
- Flexion Therapeutics
- Forest Laboratories
- Forma Therapeutics
- Fovea Pharmaceuticals
- Galapagos
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- GlobeImmune
- Gloucester Pharmaceuticals
- Grünenthal
- Helicon Therapeutics
- Hisamitsu Pharmaceutical
- Human Genome Sciences
- Human Stem Cell Institute
- Hyperion Therapeutics
- Idenix Pharmaceuticals
- Ikaria
- Incyte
- Indevus Pharmaceuticals
- Insmed
- Johnson & Johnson
- Keryx Biopharmaceuticals
- Kolltan Pharmaceuticals
- Kyowa Hakko Kirin
- La Jolla Pharmaceutical
- Lundbeck
- Lux Biosciences
- Massachusetts Biologic Laboratories
- Medarex
- The Medicines Co
- Medicis Pharmaceutical
- MedImmune
- Medivation
- Merck
- Merck Serono
- Merrimack Pharmaceuticals
- Micromet
- Molecular Partners
- Movetis
- Nabi Biopharmaceuticals
- Nektar
- NeuroSearch
- Nippon Kayaku
- Nissan Chemical
- Novartis
- Noven Pharmaceuticals
- Novexel
- NovImmune
- Nycomed
- Omeros
- Onyx Pharmaceuticals
- Ovation Pharmaceuticals
- Oxford Biotherapeutics
- PanGenetic
- Paratek Pharmaceuticals
- Peptimmune
- Pfi zer
- Plexxikon
- Portola Pharmaceuticals
- Probiodrug
- Procter & Gamble
- Prosensa
- Protalix BioTherapeutics
- Proteon Therapeutics
- PTC Therapeutics
- QLT
- Regado Biosciences
- Regeneron
- Revance Therapeutics
- Roche
- S*Bio
- Sangart
- Sanofi -Aventis
- Santaris Pharma
- Santhera Pharmaceuticals
- Schering-Plough
- Sepracor
- ShanH
- Shire
- Sigma-Tau
- Solvay Pharmaceuticals
- Sopherion Therapeutics
- Spectrum Pharmaceuticals
- Stiefel Laboratories
- Supergen
- SurModics
- Swedish Orphan
- Symphony Capital
- Synageva
- Takeda Pharmaceutical
- Talecris Biotherapeutics
- Targacept
- Targanta Therapeutics
- Teijin Pharma
- Tolmar
- Tragara Pharmaceuticals
- T-Ray Sciences
- Trellis
- Trubion Pharmaceuticals
- UCB
- Vernalis
- Vertex Pharmaceuticals
- Victory Pharma
- ViroChem
- Vitae Pharmaceuticals
- Warner Chilcott
- Wellstat Therapeutics
- Wyeth
- Xanodyne Pharmaceuticals
- Zhejiang Tianyuan Bio-Pharmaceutical
- Zogenix
- Zydus Cadila
- ZymoGenetics
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
